MD&M East

Medtronic Scores FDA Nod for Next-Gen InterStim

Medtronic continues to up its game in sacral neuromodulation. FDA approved InterStim X, the next generation of the company's InterStim portfolio's recharge-free device. Medtronic said implants have ...
MobiHealthNews

FDA approves Medtronic’s multi-implant smart programmer

The FDA has approved an app-based smart programming device used to discreetly and easily control implants treating for overactive bladder (OAB), chronic fecal incontinence (FI) and non-obstructive ...
BioWorld

Medtronic’s next-gen Interstim X system wins FDA nod

The FDA has approved Medtronic plc’s next-generation sacral neuromodulation (SNM) system, Interstim X, giving patients a recharge-free option with a 10-year+ lifespan. This newest member of the ...
Nasdaq

Medtronic (MDT) Progresses in SNM With Updated InterStim Label

Medtronic’s MDT neuromodulation business advanced recently with the company receiving FDA’s expanded MRI labeling approval for its InterStim line of sacral neuromodulation (SNM) systems. The updated ...
Becker's ASC

InterStim in the ASC Setting: 2 Surgeons Weigh In

InterStim Therapy is a sacral neuromodulation therapy from Medtronic. InterStim has been regularly used for urinary incontinence for more than a decade, but recently received additional approval as ...
WWLP-22News

Medtronic receives FDA approval for InterStim X™ system, the next generation of the most personalized sacral nerve stimulation therapy for bladder and bowel control

DUBLIN, Feb. 22, 2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced it received approval from the U.S. Food and Drug Administration (FDA) for ...
Becker's ASC

Study: InterStim Incontinence Therapy Still Effective After 3 Years

A new multicenter study shows use of Medtronic’s InterStim Therapy via sacral nerve stimulation reduced incontinent episodes and improved quality of life in most patients with chronic fecal ...